Resources
Psilocybin law timeline: every state and country
All 66 states, DC and covered countries: the law in force, when it took effect, and the bills we track. Places with a dated change come first, newest first.
- Aug 2026
- Jul 2026GeorgiaNo legal access · administrative regulation
Clinic licensing framework enacted for FDA-approved drugs
- Jul 2026
- May 2026
- Apr 2026
- Jan 2026
- Jan 2026
- Sep 2025ArizonaNo legal access · research authorization
FDA-approved psilocybin could be prescribed once rescheduled
- Jun 2025
- Jun 2025
- Sep 2024
- Jul 2024
- May 2024
- Mar 2024
- Jul 2023
- Jan 2023
- Dec 2022
- Jul 2022
- Mar 2021District of ColumbiaPartial / limited · decriminalized
Entheogenic plants a lowest enforcement priority
- Dec 2008
- Jul 2001
- May 1994
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No changeNew ZealandPartial / limited · licensed access
Individual approval for clinical psychedelic treatment
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
- No change
Research behind these laws
Peer-reviewed studies cited across PsiloAtlas.
- Bogenschutz et al. (2022) Psilocybin-assisted psychotherapy vs placebo for alcohol use disorderJAMA Psychiatry
- Carhart-Harris et al. (2021) Trial of psilocybin versus escitalopram for depressionNew England Journal of Medicine
- Davis et al. (2018) The epidemiology of 5-MeO-DMT use: benefits, consequences, patterns of useJournal of Psychopharmacology
- Davis et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorderJAMA Psychiatry
- Feifel et al. (2026) Phase 2b randomized trial of intranasal mebufotenin (BPL-003) in treatment-resistant depressionJAMA
- Goodwin et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depressionNew England Journal of Medicine
- Griffiths et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancerJournal of Psychopharmacology
- Human hallucinogen research: guidelines for safety (Johnson, Richards & Griffiths, 2008)Journal of Psychopharmacology
- Johnson et al. (2014) Pilot study of psilocybin in the treatment of tobacco addictionJournal of Psychopharmacology
- Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Cherian et al., 2024)Nature Medicine
- Mitchell et al. (2021) MDMA-assisted therapy for severe PTSDNature Medicine
- Mitchell et al. (2023) MDMA-assisted therapy for moderate to severe PTSD: a phase 3 trialNature Medicine
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (Carhart-Harris et al., 2012)PNAS
- Ot'alora G et al. (2018) MDMA-assisted psychotherapy for chronic PTSD: a randomized phase 2 trialJournal of Psychopharmacology
- Psychedelic harm reduction and integration: a transtheoretical model for clinical practice (Gorman et al., 2021)Frontiers in Psychology
- Raison et al. (2023) Single-dose psilocybin treatment for major depressive disorderJAMA
- Reckweg et al. (2023) Phase 1/2 trial of vaporized 5-MeO-DMT (GH001) in treatment-resistant depressionFrontiers in Psychiatry
- Ross et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancerJournal of Psychopharmacology